ELI Lilly is set to invest €35m in delivering a new high-tech manufacturing facility at its Kinsale campus.
ELI Lilly is set to invest €35m in delivering a new high-tech manufacturing facility at its Kinsale campus.
The company is using pioneering technology that has the potential to transform how medicines are made in the future.
The project will apply “Continuous Manufacturing Technology” to carry out the development and commercialisation of a number of Lilly’s small molecule pipeline products that are currently undergoing late-stage clinical trials.
The project implementation team, who have been working on this technology for a number of years to prove the concept, will seek to establish a fully operational facility by early 2017. This development will see the Kinsale site becoming the centre of excellence for continuous manufacturing for Active Pharmaceutical Ingredients (API) for Lilly worldwide.
This investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
For full story, see this week's Southern Star - OUT THURSDAY.
